ORTEXORTEX News
Tracking INFQ? Get live short interest, options flow, and signals on ORTEX.Sign up free →
IN
ConfluenceINFQ

INFQ Borrow Market Turns Critical as Stock Drops 25%

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 14 Jul 2026, 11:15

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Why this matters: Infleqtion's lending market has undergone a structural shift in six weeks. Availability collapsed from above 3,900% in early June to just 5.5% today. That's not noise — it's a near-total drainage of the borrowable pool, coinciding with a 25% share price decline over one month.

A Six-Week Transformation

In early June, INFQ was almost unborrowable-in-demand terms. Availability sat above 3,900% on June 3 — meaning roughly 40 shares remained available for every one already borrowed. Shorts were not meaningfully engaged.

Then something changed. Short interest began climbing steeply after June 19. By late June it had tripled. By early July it had reached 34 million shares. Availability fell in lockstep — from loose to tight to critically scarce.

As of July 13, availability stands at just 5.5%. For every 18 shares currently borrowed, only one remains available to lend. On July 8 and July 10 the figure briefly hit sub-1.3% — the tightest the borrow market has been all year.

Cost to Borrow Feels the Squeeze

Pricing has followed supply. Cost to borrow (CTB) stood at 0.36% on June 11. It now sits at 1.62% — a 57% jump in one week and a 160% rise over the month. That's still a modest absolute figure, but the direction and speed matter. Each tightening in availability has pushed CTB higher, and with availability still extremely tight, further pressure is plausible.

Short interest itself has pulled back this week — down roughly 24% from its July 8–9 peak near 34.6 million shares to around 24 million. That reduction hasn't meaningfully eased the borrow market, which suggests the shares freed up were quickly reabsorbed or that available supply has also shrunk.

Analysts Hold a Different View

Two firms initiated coverage in late June and early July. Canaccord Genuity set a Buy with a $22 target. Wedbush launched at Outperform with a $20 target. The consensus sits at Buy with a mean target of $21.

That target implies more than 100% upside from the current price of $10.13. The stock has fallen 25% over the past month and 9% in the past day alone. The gap between analyst expectations and market pricing is wide.

Earnings are due August 14. The last print, in May, sent the stock down 6% on the day before recovering over the following week.

Data Summary

  • Price: $10.13, –9.3% on the day, –24.5% over one month
  • Short interest: ~24M shares (July 13), down ~24% week-on-week; up ~700% over one month
  • Availability: 5.5% (July 13); hit 0.69% intraday low on July 8 — tightest in 52 weeks
  • Cost to borrow: 1.62%, up 57% in one week and 160% over one month
  • ORTEX short score: 65.8 (July 10), down from 68.6 two weeks prior
  • Analyst consensus: Buy; mean price target $21.00; 4 Buy ratings
  • Next earnings: August 14, 2026
  • Options PCR: 0.32, below its 20-day mean of 0.37 — call-skewed positioning

Stocks in this article

See the live data behind this article on ORTEX.

Open INFQ on ORTEX →

How this article was generated

Generated
14 Jul 2026, 11:18
Data as of
14 Jul 2026, 11:15
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.